Rigel (RIGL) Q2 FY26 earnings call

Rigel Pharmaceuticals delivered a strong second quarter, marked by robust commercial growth across its existing portfolio and the strategic in-licensing of Vepinu, a novel PROTAC for metastatic breast cancer, which is expected to be a significant growth driver. The company also advanced its R289 pipeline asset, demonstrating promising early efficacy in lower-risk MDS. Management remains focused on successful Vepinu launch, pipeline progression, and maintaining financial discipline while targeting full-year profitability.